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Abstract: Viral plaque morphologies in human cell lines are markers for growth capability and they
have been used to assess the viral fitness and selection of attenuated mutants for live-attenuated
vaccine development. In this study, we investigate whether the naturally occurring plaque size
variation reflects the virulence of the variants of EV-A71. Variants of two different plaque sizes
(big and small) from EV-A71 sub-genotype B4 strain 41 were characterized. The plaque variants
displayed different in vitro growth kinetics compared to the parental wild type. The plaque variants
showed specific mutations being present in each variant strain. The big plaque variants showed
four mutations I97L, N104S, S246P and N282D in the VP1 while the small plaque variants showed
I97T, N237T and T292A in the VP1. No other mutations were detected in the whole genome of the
two variants. The variants showed stable homogenous small plaques and big plaques, respectively,
when re-infected in rhabdomyosarcoma (RD) and Vero cells. The parental strain showed faster
growth kinetics and had higher viral RNA copy number than both the big and small plaque variants.
Homology modelling shows that both plaque variants have differences in the structure of the VP1
protein due to the presence of unique spontaneous mutations found in each plaque variant This study
suggests that the EV-A71 sub-genotype B4 strain 41 has at least two variants with different plaque
morphologies. These differences were likely due to the presence of spontaneous mutations that are
unique to each of the plaque variants. The ability to maintain the respective plaque morphology
upon passaging indicates the presence of quasi-species in the parental population.
Keywords: EV-A71; epidemiology; recombination; quasi-species; spontaneous mutations; virulence
1. Introduction
Enterovirus 71 (EV-A71) belongs to the genus Enterovirus within the family Picornaviridae. It is a
common etiological agent of hand, foot and mouth disease (HFMD) which was first isolated from a
young child in the USA in 1969 [1]. It is capable of causing severe neurological diseases which range
from encephalitis to acute flaccid paralysis and cardiopulmonary complications which can lead to
death [2]. Although EV-A71 has been reported to cause infections in many countries [2–5], massive
outbreaks caused by EV-A71 especially in Asia-Pacific countries such as China, Taiwan and Malaysia
are particularly worrisome [6–9].
Human enteroviruses such as EV-A71 are non-enveloped and contain single-stranded,
positive-sense RNA of approximately 7.4 kb [10]. The genome contains two non-coding regions, the
5′-NTR and the 3′-NTR that flank a single open reading frame (ORF) [11]. All four structural proteins
(VP1-VP4) are encoded by the P1 region of the genome while P2 and P3 encode for the non-structural
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proteins 2A–2C and 3A–3D [10,12]. The complete phylogenetic analysis of EV-A71 based on the
structural VP1 gene identified seven independent lineages: A, B, C, D, E, F and G [13]. Group A
consists of the prototype BrCr strain only. Group B is divided into the sub-genotypes B1–B5 which
are predominant in Malaysia and Singapore. The C group could be further subdivided into C1–C5
whereby the sub-genotypes C2 and C4 are predominant in China and Vietnam [2,12].
The evolution of EV-A71 has been established to occur naturally and recombination is the
fastest way for EV-A71 to evolve, often resulting in novel genomic regions with high diversity when
compared to the parental genome [14]. In turn, these new genomic regions may drive a change in
the characteristics of the virus such as its virulence [15]. Notably, it was reported that EV-A71 has
established its endemicity in the Asia-Pacific region with different circulating strains which include
sub-genotypes C1,C2, B3 and B4 [16,17]. Interestingly, another factor that has an impact on the viral
pathogenesis in EV-A71 is the occurence of spontaneous mutations. There are numerous reports of
single mutations occurring in the genome of EV-A71 that had significantly affected its virulence [18–22].
Multiple changes in the characteristics of EV-A71 caused by these spontaneous mutations could
also mediate the evolution of EV-A71. The high divergence of EV-A71 strains circulating in the
human population occurred as a consequence of the low fidelity of the 3D RNA-dependent RNA
polymerase [15]. The distinctive feature of the viral RNA polymerase used by RNA viruses to induce
high mutation rates often results in a swarm of mutant viruses [23].
Many different studies attest to the presence of distinct genetic variants arising from wild type
viruses. Dengue virus serotype 2 was observed to exhibit mixed plaque phenotypes in LLC-MK cells.
Small plaque variants selected from the mixed population were temperature sensitive in LLC-MK cells
and became attenuated in suckling mice [24]. Similarly, another study examined the determinants of
small plaque phenotype using two different Dengue virus (DENV) vaccine candidate strains: DENV-3
PGMK30FRhL3 and DENV-2 PDK53. It was observed that DENV-3 PGMK30FRhL3 produced small
plaques in BHK-21 cells due to its slow in vitro growth rate. However, DENV-2 PDK53 replicated
quickly but was unable to evade antiviral responses that constrained its spread; hence it also gave
rise to small plaques. It was concluded that at least two molecular mechanisms govern plaque
phenotypes in DENV 2 [25]. Likewise, two different plaque variants of Japanese encephalitis virus
(JEV) were characterized from the wild-type (WT) whereby the small plaque variant displayed delayed
replication kinetics in Vero cells and was resistant to neutralization by monoclonal antibodies [26].
Moreover, Dengue virus serotype 4 (DENV-4) was observed to display small plaque phenotypes with
attenuated pathogenicity in mice [27–29]. Neuroblastoma cell-adapted yellow fever 17D virus also
exhibited the small plaque morphology (SPYF). The virulence properties of the small plaques were
distinguishable from non-neuroadapted viruses (YF5.2iv, the infectious clone) whereby it presented
decreased average survival time in severe combined immunodeficient (SCID) mice after peripheral
inoculation. SPYF also exhibited more efficient growth in peripheral tissues of SCID mice compared to
YF5.2iv. This resulted in a quicker accumulation of viral burden but resulted in low-titer viremia at the
onset of fatal encephalitis [30,31]. More recently, other viruses were observed to display mixed plaque
phenotypes in varying cell lines whereby the plaque variants (big or small) were capable of displaying
different levels of virulence in vitro and in vivo [25,32–34]. Small plaque variants of chikungunya virus
(CHIKV) showed stable homogenous small plaques after four plaque purifications and grew slower
with lower titres when compared to the WT virus [35]. Of particular interest, the Zika virus (ZIKV)
derived from Asian/American lineage formed small and large plaques with consistent amino acid
differences (230Gln for small plaque variants and 230Arg for big plaque variants) in each of the variants.
The growth kinetics of the virus clone derived from the large plaque variant was faster than the virus
clone derived from the small plaque variant and the amino acid at position 230 in the viral polyprotein
is a molecular determinant for plaque morphology, growth characteristics and virulence in mice [34].
In an attempt to characterize the small plaque variants of West Nile Virus (WNV), it was discovered
that the SP variant replicated less efficiently than the WT in Vero cells whereas the SP growth was
severely restricted at high temperatures in avian cells. Relative to the WT, the SP phenotype exhibited
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reduced replications and lower infections when administered via different inoculation routes. Analysis
of the SP variant identified two amino acid substitutions (prM P54S and NS2A V61A) relative to the
WT. These mutations were observed to affect the ability of progeny viruses to infect BHK cells which
led to attenuated neurovirulence and neuroinvasiveness of the virus [33].
In this study, the wild-type EV-A71 sub-genotype B4 strain 41 was observed to display small
and big plaque variants when growing in Rhabdomyosarcoma (RD) and Vero cells. How these
phenotypically different plaque variants of EV-A71 could affect virulence have not been previously
explored. We report here how the small-plaque (SP) variant selected from the wild-type EV-A71 strain
41 (Enterovirus 5865/sin/00009) showed a different level of virulence compared to the big plaque (BP)
variant when tested in vitro through the analysis growth kinetics, plaque formation, RNA copy number
and viral binding. Nucleotide sequencing and 3D homology modelling of the VP1 of the EV-A71 were
carried out to investigate how changes in amino acid residues in the big and small plaque variants
could affect virulence in vitro.
2. Materials and Methods
2.1. Cell Lines
Human Rhabdomyosarcoma RD (ATCC® CCL136™) cells were grown in Dulbecco’s modified
minimal essential medium (DMEM) (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum (FBS) (Gibco, Carlsbad, CA, USA), 1% non-essential amino acid and 1% penicillin/streptomycin.
The cells were grown at 37 ◦C supplemented with 5% CO2 until desired confluency was achieved
(70–90%).
2.2. Serial Passages of Virus
All EV-A71 viruses (Enterovirus 5865/sin/00009) were grown in RD cell monolayers in DMEM
supplemented with 2% fetal bovine serum 2 MmL-glutamine, and 1% penicillin/streptomycin at 37 ◦C.
The wild type EV-A71 sub-genotype B4 strain 41 at MOI 1 was added to the monolayer of cells and
incubated for 1 h. Then, the viral supernatant was discarded, and the cells were washed with 1× PBS
and fresh media (DMEM, 2% FBS and 1% PSA) was added. Next day, the virus was harvested by three
cycles of freeze-thawing and the viral supernatant was stored at −80 ◦C.
2.3. Plaque Assay
Approximately 8 × 105 RD cells/mL were seeded into each well of a 6-well plate and maintained
in the complete growth medium. Prior to viral infection, the complete growth medium was removed
and washed twice with 1× PBS and then infected with the viral inocula prepared at different serial
dilutions of virus stock suspension. After viral adsorption for 1 h at 37 ◦C, the inocula were removed,
the cells were washed twice with 1× PBS and then overlaid with 1 mL plaque medium (containing 1.2%
carboxymethylcellulose and 2% FBS). After 72 h of incubation, cells were fixed with 3.7% formaldehyde
and stained with 0.5% crystal violet. Plaque forming units were counted.
2.4. Isolation of Plaque Variants
Approximately 8 × 105 RD cells/mL were seeded into each well of a 6-well plate and maintained in
the complete growth medium. Prior to viral infection, the complete growth medium was removed and
washed twice with 1× PBS and then infected with viral inoculum prepared at different serial dilutions
(10−1 to 10−10) of the virus stock suspension. After viral adsorption for 1 h at 37 ◦C, the inocula were
removed, the cells were washed twice with 1× PBS and then overlaid with 2 mL of DMEM with 2%
FBS and 1%PSA containing 1.5% of agarose as the overlaying media (Hydragene, Xiamen, China).
The overlay was allowed to solidify before incubation at 37 ◦C for 3 days. After 3 days, the plaques
were marked with a pen under the microscope. Using a sterile glass pipette tip, an agarose plug was
removed directly over the plaque. Each plaque that was picked up was added to separate wells of
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a 24-well tissue culture plate seeded with 4 × 105 cells per well in 500 mL of fresh DMEM media.
The plates were incubated at 37 ◦C overnight before harvesting the virus plaque variants.
2.5. Re-Infection of the Cells by EV-A71/BP and EV-A71/SP Plaque Variants and the Determination of Their
Plaque Sizes
Isolated plaques were used to infect RD and Vero cells in 6-well plates at different viral dilutions.
After viral adsorption for 1 h at 37 ◦C, the inocula were removed, the cells were washed twice and then
overlaid with 2 mL of DMEM with 2% FBS and 1%PSA containing 1.5% of agarose overlay (Hydragene,
Xiamen, China). The overlay was allowed to solidify before incubation at 37 ◦C for 3 days. After
72 h of incubation, the cells were stained for 6 h with crystal violet stain (Sigma, St. Louis, MO, USA)
before plaques were observed. Plaques were examined and images of the whole well were captured
with an Immunospot® S6 VERSA Analyzer (Cellular Technology Limited, Shaker Heights, OH, USA).
Diameters of plaque variants in monolayers of RD and Vero cells were determined. For each plaque
variant, at least 400 plaques were measured using the DS-L3 viewer with the Nikon’s NIS-Elements
software and analysed by Graph pad prism 7.04.
2.6. Growth Kinetics
RD and Vero cells at a density of 8 × 105 cells/mL were seeded within the wells of multiple 6-well
plates. When the desired confluency was achieved, the cells were washed with 1× PBS and infected
with each viral plaque variant in triplicates at a MOI of 0.1 and incubated for 60 min at 37 ◦C. After this,
the virus inoculum was discarded, and the RD and Vero cells were washed with 1× PBS before being
replaced with reduced growth media (DMEM supplemented with 2% FBS and 1% PSA). The virus
supernatants were harvested at 12 h, 24 h, 48 h and 72 h post-infection (h.p.i) and were subsequently
kept at −80 ◦C for downstream processes such as the determination of RNA replication expressed as
viral copy number using RT-qPCR and infectivity in PFU/mL using plaque assay.
2.7. Rates of RNA Replication (RT-qPCR)
Primers targeting the VP1 sequence of the EV-A71 were adopted from a previous
study [36]. The forward primer employed was 5′-GAGCTCTATAGGAGATAGTGTGAGTAGGG-3′,
the reverse primer was 5′-ATGACTGCTCACCTGCGTGTT-3′ and the TaqMan probe used was
5′6-FAM-ACTTACCCA/ZEN/GGCCCTGCCAGCTCC-lowa Black FQ-3′. The viral RNA samples
were extracted using QIAamp Viral RNA mini kit (QIAGEN, Hilden, Germany) according to the
manufacturer’s instructions. The RT TaqMan real-time PCR assay was performed with the C1000
Touch Thermal Cycler CFX96 Real-time System (BIORAD, Hercules, CA, USA) using TaqMan® Fast
virus 1-step master mix (ThermoFisher Scientific, Waltham, MA, USA) with cDNA synthesis by reverse
transcription for 5 min at 50 ◦C and subsequently amplified for 40 cycles at 95 ◦C for 3 s, 60 ◦C for
30 s. Three independent experiments were conducted for each sample. The threshold cycle value (Cq)
was determined using default threshold settings, and the mean Cq was calculated from the PCR runs
in triplicates. A standard graph was plotted based on a series of standard solutions containing the
EV-A71 RNA samples from 10−1 to 10−6.
2.8. Amplification of EV-A71 RNA to cDNA
Viral RNA was isolated from the EV-A71 plaque isolate using QIAmp® Viral RNA Mini Spin Kit
(Qiagen, Hilden, Germany). The kit was used according to the manufacturer’s instructions. The purified
RNA was reverse transcribed into single-stranded DNA by using the SuperScriptTM IV First Strand
Synthesis System (ThermoFisher Scientific, Waltham, MA, USA). Each cDNA synthesis mixture
contained 10× annealing buffer, 25 mM MgCl2, SuperScript® IV RT and the viral RNA as template.
Viral double-stranded cDNA was amplified with LongAmp® Taq DNA Polymerase (NEB, Ipswich,
MA, USA) using designed primer sets. Agarose gel (0.5%) was prepared in 1× Tris-acetate-EDTA (TAE)
buffer. SYBR™ Safe DNA Gel Stain (Invitrogen, Carlsbad, CA, USA) was added to the agarose gel at
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final concentration of 0.5 µg/mL. Gel Loading Dye Purple (6×) (NEB, Ipswich, MA, USA) was mixed
with the DNA samples before loading into the wells of the gel. The GeneRuler 1 kb DNA Ladder
(ThermoFisher Scientific, Waltham, MA, USA) was used to determine the size of the DNA (dsDNA)
fragments in the gel. PCR products were verified as being successfully amplified and they appeared as
bright distinct bands on the agarose gel following electrophoresis at 95 V for 90 min.
2.9. Genome Sequencing
After the PCR products were confirmed by agarose gel electrophoresis, the PCR products were
sequenced using designed primers. Raw sequencing data were assembled to reconstruct the complete
EV-A71 genome using the Geneious Software (Biomatters, Auckland, New Zealand) and Clustal
Omega (Conway Institute UCD, Dublin, Ireland) See Supplementary Table S1: Primers used for the
whole genome sequencing of EV-A71.
2.10. Homology Modelling
The VP1 protein of the EV-A71 parental strain, the big and small plaque
variants, were modelled using YASARA Structure (“Yet Another Scientific Artificial Reality
Application”, http://www.yasara.com) Software. The VP1 three-dimensional (3D) crystal structures
of four human enterovirus A71 (PDB ID: 4AED, 6I2K, 4CDQ and 3VBF) with sequence identity
of more than 95% were used as the templates by homology search from The National Center for
Biotechnology Information (NCBI) and Protein data bank (PDB) database. The predicted model
was subjected to energy minimization by YASARA software. Then, the model was validated
using pdbsum (http://www.ebi.ac.uk/thornton-srv/databases/pdbsum/Generate.html), Verify 3D
(http://servicesn.mbi.ucla.edu/Verify3D/) and ERRAT (http://servicesn.mbi.ucla.edu/ERRAT/) programs.
(Supplementary Table S2: PSI-BLAST of the VP1 protein sequence of the EV-A71 parental strain.)
2.11. Viral Binding Assay
In order to examine the virus binding ability by ELISA, 2.0 × 104 cells/mL of RD and Vero cells
were seeded into each well of a 96-well plate and maintained in complete growth media for 1 day.
Prior to viral infection, the complete growth media was removed, and the cells were washed with 1×
PBS and then infected with viral inocula of plaque isolates at MOI of 10 and incubated for 1 h at 4 ◦C.
Unbound viruses were washed away with cold 1× PBS. Cells were then fixed with 80% acetone and
stained with monoclonal Enterovirus 71 VP1 antibody (GeneTex, Irvine, CA, USA) at 1:2000 dilution in
1%BSA for 1 h. This was followed by washing with PBS-T (0.05% Tween 20 in PBS) and staining with
mouse anti-goat IgG HRP (Santa Cruz Biotechnology, Dallas, TX, USA) at 1:2000 dilution in 1% BSA
for 1 h. Once washed with PBS-T, KPL TrueBlue™ Peroxidase Substrate (50 µL) (Sera Care Life Science,
Milford, MA, USA) was added to all infected cells within each well and the absorbance was measured
using Infinite® 200 PRO (Tecan, Männedorf, Switzerland) at 650 nm.
3. Results
3.1. Isolation of Big-Plaque and Small-Plaque Variants of EV-A71
In both RD and Vero cells, the wild type (EV-A71/WT) sub-genotype B4 strain 41 (5865/sin/000009)
population exhibited mixed-plaque phenotypes represented by both big and small plaque variants
designated as EV-A71/BP and EV-A71/SP, respectively (Figure 1A,D). Isolation of these individual
plaque variants led to the observation that EV-A71/BP variants displayed uniformly big plaque
phenotype in both RD and Vero cells (Figure 1B,E). In contrast, the EV-A71/SP variants produced very
tiny, pin-sized plaques compared to the larger plaque variants observed in the EV-A71/BP populations
in both cell lines (Figure 1C,F). Subsequently, the diameter of 400 plaques from the EV-A71/BP and the
EV-A71/SP populations were measured. The EV-A71/SP observed in RD cells were significantly smaller
(mean: 0.293 ± 0.002 mm) than those of the EV-A71/BP (0.519 ± 0.004 mm; p < 0.01, t-test) (Figure 1G).
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Furthermore, EV-A71/SP virus variant in Vero cells (mean: 0.177 ± 0.002 mm) were significantly
smaller than those of the EV-A71/BP variant (0.380 ± 0.003 mm; p < 0.01, t-test) (Figure 1H). The results
showed that there was a significant size difference amongst all the isolates exhibiting the small plaque
morphology when compared to all the isolates exhibiting the big plaque morphology.
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Figure 1. Plaque morphology of the (A) Parental WT strain, (B) big plaque variant (EV-A71/BP), and
(C) the small plaque (EV-A71/SP) variant cultured in RD cells. Plaque morphology of the (D) Parental
WT strain, (E) the big plaque (EV-A71/BP) variant, and (F) the small plaque (EV-A71/SP) variant
when cultured in Vero cells. Cells within the wells of a 6-well plate were infected with the wild
type EV-A71 (5865/sin/000009) or the EV-A71/BP and EV-A71/SP. The plaques were visualised 72 hpi
(hours post infection) after staining with crystal violet. Plaques were examined and images of the
whole well were captured with an Immunospot® S6 VERSA Analyzer (Cellular Technology Limited,
Shakers Heights, OH, USA). Diameters of plaque variants in monolayers of RD and Vero cells were
determined. For each plaque variant, at least 400 plaques were measured using the DS-L3 viewer with
the Nikon’s NIS-Elements software and analysed by Graph pad prism 7.04. The mean plaque size of
all isolates exhibiting small plaque morphology were compared against the mean plaque size of all
isolates exhibiting big plaque morphology in (G) RD and (H) Vero cells. Statistical analysis, unpaired
t-test, **** p < 0.0001. See Supplementary Table S3: Unpaired t-test analysis of the EV-A71/BP and the
EV-A71/SP plaque variant using GraphPad Prism.
3.2. In Vitro Assessment of the Big and Small Plaque Variants
The ability of the two EV-A71 variants to form plaques of different morphologies was evaluated
in both RD and Vero cells (Figure 2A,B). The big plaque variants produced the highest number
of plaques (5.62 × 109 ± 6.40 × 108 PFU/mL) in RD cells but had lower viral titres in Vero
cells (1.32 × 104 ± 603.5 PFU/mL) (Table 1). Lesser number of viral plaques (one log less) were
observed for the small plaque variants in RD (6.35 × 108 ± 6.25 × 108 PFU/mL) and Vero cells
(6.05 × 103 ± 455.5 PFU/mL). Since the ability to form plaques was reduced for the small plaque
variant, viral growth was confirmed to be lower. Lower viral growth indicated lower virulence of the
small plaque variant in RD and Vero cells.
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Table 1. Plaque forming ability of EV-A71 big plaque variants and small plaque variants in RD and
Vero cells.
Plaque Variants of EV-A71 * Viral Titre in RD Cells (PFU/mL) Viral Titre in Vero Cells (PFU/mL)
SP1 3.7 × 108 6.40 × 103
SP2 8.7 × 108 6.70 × 103
SP3 9.9 × 108 6.40 × 103
SP4 7.0 × 108 4.70 × 103
BP1 5.4 × 109 1.39 × 104
BP2 5.5 × 109 1.18 × 104
BP3 6.4 × 109 1.44 × 104
BP4 8.1 × 109 1.25 × 104
* SP1–SP4 denotes all small plaque variants and BP1–BP4 denotes all big plaque variants used in this study.
Viral titres were quantified in Rhabdomyosarcoma (RD) and Vero cells, respectively.
3.3. Rates of RNA Replication and Infectivity of EV-A71/BP and EV-A71/SP Plaque Variants
Both EV-A71 plaque variants had lower RNA replication rates in RD and Vero cells when compared
to the wild type (EV-A71/WT) (Figure 3A,B). Overall, the EV-A71/WT (coloured in black) was observed
to display significantly better rates of RNA replication when compared to the EV-A71/BP (coloured
in blue) and EV-A71/SP variants (coloured in magenta). Meanwhile, the EV-A71/SP had the lowest
rate of RNA replication when compared to both the EV-A71/WT and the EV-A71/BP variant. A sharp
increase in the overall RNA rates of replication was observed from 12 hpi onwards in RD cells for
the EV-A71/WT and the two plaque variants (Figure 3A). Subsequently, the rate of replication was
observed to plateau at 72 hpi for the EV-A71/BP (1.29 × 108 viral copy number) while the replication of
the EV-A71/SP (1.127 × 108 viral copy number) variant was observed to decline at 72 hpi. However, the
EV-A71/WT continued to increase to 1.67 × 108 viral copy number at 72 hpi. Thus, the most significant
difference was observed to occur between the overall viral RNA copy number of the EV-A71/SP variant
and the EV-A71/WT (p < 0.01, one-way ANOVA).
On the other hand, replication of the EV-A71 in Vero cells was observed to lag by 12 h when
compared to the RD cells whereby the rate of replication was only shown to rise sharply after 24 hpi
(Figure 3B). There was a slight difference in the RNA copy number between the EV-A71/WT and the
two plaque variants at 24 hpi. The difference became greater as the infection progressed to 24, 48 and
72 hpi. The significant difference in RNA copy number between the EV-A71/WT and the EV-A71/SP
was 3.225 × 109 viral copy number (p < 0.05, one-way ANOVA). Additionally, it was intriguing to
observe that the peak RNA copy number in Vero cells for the EV-A71/WT, EV-A71/BP and EV-A71/SP
variants was one log higher than the peak RNA copy number of the EV-A71/WT and the EV-A71 plaque
variants in RD cells. Overall, these results suggested that the replication kinetics of the wild type
parental strain (EV-A71/WT) was significantly higher than the two EV-A71 plaque variants independent
of the host cell lines used in this study.
To further clarify the viral replication rates of the two EV-A71 plaque variants with respect to the
wild type, we next compared their kinetics of infectivity at different time points to gain an understanding
of the rate of infectivity. The parental strain displayed significantly higher levels of infectivity when
compared to both the EV-A71/BP and EV-A71/SP variants (Figure 3C,D). The EV-A71/BP variant
displayed higher levels of infectivity compared to the small plaque variant which was consistent
with the general pattern observed in RNA replication in the RD cells. However, no significant
difference in the levels of infectivity was observed between the EV-A71/BP and EV-A71/SP variant in
RD cells. The infectivity of the EV-A71/WT in RD cells peaked at 24 hpi (1.185 × 108 PFU/mL) while
the EV-A71/BP and EV-A71/SP variants lagged by 24 h and peaked at 48 hpi (3.125 × 107 PFU/mL
and 2.2 × 107 PFU/mL respectively) before decreasing to substantially lower titres (Figure 3C).
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Figure 3. Comparison of rates of RNA replication of wild-type (WT), big plaque (BP) and small
plaque (SP) variants in vitro in (A) RD and (B) Vero cells. RD and Vero cells in wells within the 6-well
plates were infected with EV-A71/WT, EV-A71/BP and EV-A71/SP variants in triplicates at a MOI of
0.1 PFU/mL. Viral supernatants were harvested from the medium at 12, 24, 48 and 72 hpi and subjected
to qRT-PCR in triplicates to obtain the rates of RNA replication in viral copy number. The EV-A71/WT
is shown in black, EV-A71/BP is depicted in blue and EV-A71/SP is coloured magenta. Infectivity of the
EV-A71 plaque variants (EV-A71/BP and EV-A71/SP) and the parental strain (EV-A71/WT) in (C) RD
cells and (D) Vero cells. The WT strain is shown in black while the big plaque variant (EV-A71/BP) is
displayed in blue and the small plaque variant (EV-A71/SP) is in magenta. Statistical analysis used was
unpaired t-test; * p < 0.05, ** p < 0.01, **** p < 0.0001 and NS indicates no significance.
In Vero cells, the rates of infectivity of both plaque variants (EV-A71/BP and EV-A71/SP) were
significantly lower than the EV-A71/WT. The maximum infectivity was 6.2 × 105 PFU/mL at 72 hpi
for the EV-A71/WT but the EV-A71/BP variant showed much lower titre than the EV-A71/WT with
2.85 × 105 PFU/mL at 72hpi (Figure 3D). The infectivity of the EV-A71/SP variant in Vero cells was
undetectable at 12 and 24 hpi and very low titres were detected throughout infection from 48 hpi
onwards (1 × 104 PFU/mL at 72 hpi). At 72 hpi, the difference in titres between the EV-A71/WT and
the EV-A71/SP variant was one log difference (6.2 × 105 PFU/mL when compared to 1 × 104 PFU/mL).
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The growth kinetics of the EV-A71/WT in comparison with both plaque variants, EV-A71/BP and
EV-A71/SP, in terms of the rate of RNA replication and infectivity showed that the small plaque variant
(EV-A71/SP) had lower kinetics of growth than the EV-A71/WT and the EV-A71/BP variants at all
time–points of sampling in both RD and Vero cells.
3.4. Sequence Comparison of Small-Plaque and Big-Plaque Variants to the WT
The differences in plaque morphology, growth kinetics and in vitro infectivity observed could be
due to the presence of mutations present in the genomes of the EV-A71/BP and EV-A71/SP variants.
To confirm whether there are mutations present in the EV-A71/BP and EV-A71/SP variants, the entire
genome of each EV-A71 plaque variant was amplified and sequenced via Sanger sequencing and
compared with the full genome of the sequenced EV-A71/WT. (Supplementary Figure S1: Agarose
gel electrophoresis of the full-length genomic cDNA of EV-A71/WT and Supplementary Figure
S2: Raw genome sequencing data of EV-A71/BP and EV-A71/SP). Comparison of the EV-A71/WT
sequence against the genome of the four EV-A71/BP variants revealed the presence of the same
four non-synonymous mutations present in the VP1 region, namely: I97L, N104S, S246P and N282D
(Figure 4A). Likewise, analysis of the four EV-A71/SP variants showed three non-synonymous mutations
present in the VP1 region, namely: I97T, N237T and T292A (Figure 4B). These results suggest that any
of these non-synonymous mutations present in the EV-71/BP and EV-71/SP variants could account
for the differences in plaque morphologies and infectivity observed in vitro in RD and Vero cells.
See Supplementary Table S4: Amino acid changes observed on the genomes of EV-A71/BP and
EV-A71/SP variants.
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Figure 4. (A) The VP1 amino acid sequence of the WT (parental EV-A71 strain) against EV-A71/BP.
Significant non-synonymous mutations are: I97L, N104S, S246P and N282D. (B) The VP1 amino acid
sequence homology of the WT (parental EV-A71 strain) and the EV-A71/SP was performed using
Clustal Omega. Significant non-synonymous mutations are: I97T, N237T and T292A in the VP1 of the
EV-A71/SP.
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3.5. Analysis of Amino Acid Mutations in the VP1 of the EV-A71 Plaque Variants
To understand how the non-synonymous mutations, present in the big and small plaque variants
could affect the interaction of the virus with the RD or Vero cells, the contribution of each mutation
towards protein folding and stability was analyzed by 3D modelling. The modelling process involved
several steps, such as target template selection and model building. The accuracy of the models
increased along with the increase in the number of known, close and high-resolution protein structures.
Since the VP1 three-dimensional (3D) structure of the EV-A71 sub-genotype B4 strain 41 was not found
in the protein data bank, it was necessary to model the EV-A71 parental strain prior to using it as a
reference for analysis of theEV-A71 plaque variants. The model was built using YASARA Structure
(17.4.17) software. (Supplementary Figure S3: The 3D structure of the VP1 protein of the EV-A71/WT
superposed against the EV-A71/BP and EV-A71/SP variants.)
The big plaque variant, EV-A71/BP, was observed to carry four mutations (I97L, N104S, S242P and
N282D) in its genome which caused differences in the 3D structure of the VP1 protein compared to the
wild-type strain, EV-A71/WT. The mutation found at position 97 (EV-A71/SP: I97T and EV-A71/BP: I97L)
is of significant interest as it is found in the BC loop of the VP1 protein and appears to be a recurrent and
favoured spot for mutation in all EV-A71/BP and EV-A71/SP variants. In the EV-A71/WT, isoleucine
(I) is found at position 97, but mutation to either threonine (T) or leucine (L) in the EV-A7/BP and
EV-A71/SP variants, respectively, caused the formation of new hydrogen bonds (Figures 5A and 6A).
For instance, changing isoleucine (I) to threonine caused the latter to form a single hydrogen interaction
with serine (S) at position 243. In the big plaque variant, a hydrogen bond was formed between serine
(S) at position 243 and tyrosine (Y) at position 245. Moreover, despite the change in amino acid at
position 104 (asparagine to serine) in the EV-A71/BP variant, no change in the characteristics of the
amino acid was observed as both asparagine and serine belong to the same family of amino acids with
polar uncharged side chains (Figure 5B). Interestingly in the EV-A71/WT, Asn104 (asparagine) initially
formed a single hydrogen bond with Arg166 (arginine) which in turn interacted with Ser240 (serine).
However, when asparagine (N) was substituted with Ser104 (serine) in the EV-A71/BP variant, it formed
two hydrogen bonds with the Arg166 (arginine) and no interactions were observed with Ser240 (serine).
At position 246 of the EV-A71/BP, the mutation induced a change in the characteristics of the amino
acid such that a polar uncharged amino acid (serine) was replaced with the proline residue (Figure 5C).
Of significant interest is the position at 282 near the N-terminus of the VP1 protein, whereby the polar
uncharged asparagine (N) was replaced by aspartic acid (D) which has a negatively charged side
chain. When asparagine (N) was found at position 282 in the EV-A71/WT, the neighbouring amino
acid residue, Ser283, interacted via a single hydrogen bond with the Ala280. However, when mutation
induced a change to aspartic acid (Asp282), the latter gained an additional hydrogen bond interaction
with Ala280 (Figure 5D).
All three mutations (I97T, N237T and T292A) identified in the VP1 of the EV-A71/SP variants
contributed to the difference observed in the 3D structure of the VP1 protein when compared to the
EV-A71/WT. Besides the mutation I97T, two other mutations (N237T and T292A) were discovered to
play a role in affecting the folding of the VP1 protein of the EV-A71/SP variant. For instance, mutation
at position 237 caused asparagine (Asn237) to change to threonine (T). As a result, this induced the
formation of two hydrogen bonds with neighbouring residue glycine (Gly105) found in the pocket
factor of the VP1 protein (Figure 6B). The last amino acid substitution was observed at position 292
(threonine to alanine) which was present on the surface of the capsid (Figure 6C). In the EV-A71/WT,
threonine at position 292 (Thr292) interacted with leucine (Leu297) via two hydrogen bonds. However,
mutation of Thr292 to Ala292 resulted in the loss of one hydrogen bond in the interaction with Leu297.
In addition, substitution of threonine, which is a polar uncharged amino acid, with alanine increased
the hydrophobicity of the amino acid in the EV-A71/SP.
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Figure 6. A close up view of the three mutations (A–C) observed in the EV-A71/SP structure (bottom
row) when compared with the EV-A71/WT (top row). Amino acid substitutions are underlined and the
hydrogen bonds are observed as yellow dotted lines.
It can be observed that these mutations and their characteristics contributed to the structural
differences in the VP1 protein of the EV-A71/BP and EV-A71/SP variants by interacting with neighbouring
amino acid residues.
3.6. Impact of Spontaneous Mutations on VP1 Protein Folding
While the overall folding conformation of the VP1 proteins of EV-A71/BP and EV-A71/SP variants
appear to remain mostly unaffected, it was observed that there are significant structural variations
between the wild type structure and the EV-A71 plaque variants (Table 2). The secondary structure
analysis of the EV-A71/WT and the two plaque variants showed that the VP1 protein of the EV-A71/WT
contained nine helical structures and several intermediate loops. However, a loss of α-helix was
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observed in the EV-A71/BP variant, which contained seven helices while the EV-A71/SP had six helices
only. The loss of two α-helices seen in the EV-A71/BP was also accompanied by the increase in turn
and 310 helices in the structure of the EV-A71/BP variant. On the other hand, the loss of two α-helix
structures in the EV-A71/SP was associated with a rise in turn and coil structures (Table 2). Upon closer
examination, it was observed that the new mutations induced changes in the cytosolic GH loop
(residue 202–222) of the VP1 of the EV-A71/BP and EV-A71/SP variants in contrast with the EV-A71/WT.
The helical GH loop in the EV-A71/WT was changed to a coiled structure in the EV-A71/SP variant.
However, the EV-A71/BP variant only exhibited partial loss of the helical conformation and displayed
within its GH loop a 310 helical structure instead (Figure 7).
Table 2. Comparison of structural analysis of the EV-A71 plaque variants compared to the wild-type.
EV-A71 Variants RMSD/Å Hydrogen Bonds Interactions Secondary Structure Content
EV-A71/WT 0.00 108 9.4% helix, 23.9% sheet, 17.5%turn, 47.8% coil, 1.3% 310 helix.
EV-A71/BP 1.76 104 6.7% helix, 23.2% sheet, 20.9%turn, 47.5% coil, 1.7% 310 helix.
EV-A71/SP 1.35 107 7.4% helix, 23.2% sheet, 19.9%turn, 48.1% coil, 1.3% 310 helix.Viruses 2020, 12, x FOR PEER REVIEW 13 of 24 
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3.7. Viral Binding Ability
Analysis of the VP1 structure via structural modelling showed that the mutations uncovered
through Sanger sequencing were responsible for the alterations of the VP1. The superimposition of
the EV-A71/BP and EV-A71/SP variants against the EV-A71/WT showed structural changes in the GH
loop. The GH loop region of the VP1 capsid has been previously established to play a crucial role
in exhibiting interaction between EV-A71 and its cellular receptor(s). It is therefore likely that the
mutations affecting the structure of the GH loop are involved in influencing the virus binding ability of
the EV-A71 in RD and Vero cells.
The results demonstrated that the viral binding of the EV-A71 plaque variants (EV-A71/BP and
EV-A71/SP) was significantly reduced in both cell lines. In both host cells, the EV-A71/WT exhibited
the highest binding ability compared to the EV-A71/BP and EV-A71/SP variants. Statistical analysis
used was one-way ANOVA, p < 0.05.
In RD cells, the EV-A71/BP demonstrated a significant loss in binding ability of 11% compared to
the EV-A71/WT. However, the loss in binding capacity of the EV-A71/SP was significantly higher at
17% compared to the EV-A71/WT (Figure 8A). When Vero cells were used, the binding capacity of the
EV-A71/BP variant was higher than the EV-A71/SP variant by 8%. However, the loss in binding ability
of the EV-A71/BP compared to the EV-A71/WT was only at 10%. Much like that being observed in RD
cells, there was a 17% loss in binding capabilities for the EV-A71/SP in contrast with the EV-A71/WT
(Figure 8B).
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Figure 8. Contribution of mutations of the EV-A71/BP and EV-A71/SP variants to the virus binding
ability was determined by ELISA in (A) RD cells and (B) Vero cells. The EV-A71/WT is displayed as the
reference. Data represent the averages from at least three independent experiments ±SD, Statistical
analysis used was one-way ANOVA, * p < 0.5, ** p < 0.01, *** p < 0.001 and NS indicates no significance.
4. Discussion
EV-A71 continues to be a significant public health threat in Asia. Being one of the main etiological
agents of HFMD, EV-A71 has the capability to cause severe neurological complications such as
acute flaccid paralysis, neurological pulmonary oedema and even deaths, mainly in children [37].
Hence, it is vital to understand the underlying cause of attenuation as well as the selection process of
virulent strains.
The evolution of EV-A71 strains within a viral population could arise from recombination and
spontaneous mutations [14]. The observation of the viral variants exhibiting big and small plaque
morphologies clearly indicate the existence of viral variants carrying different mutations in their
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genomes. In this study, we showed that the wild-type population of EV-A71 sub-genotype B4 strain
41 contained at least two genotypes: big and small plaque variants which exhibited two different
morphologies in terms of their plaque sizes. The persistence of the mutations in the genomes of the big
and small plaque variants confirmed the presence of at least two quasi-species in the EV-A71 wild
type population. Thus, this study shows for the first time the two EV-A71 plaque variants exhibiting
genotypic differences and their in vitro virulence in RD and Vero cells.
The morphology of the EV-A71/SP and EV-A71/BP variants was reflected in the determination of
plaque sizes following the selection of the EV-A71 variants. RD cells significantly demonstrated clearer
resolution of plaque sizes for both variants when compared to the Vero cells. This difference in plaque
sizes across diverse cell lines was demonstrated in a previous study which showed that RD cells were
more sensitive and receptive to EV-A71 infections [38]. This could explain why, in general, the plaques
observed in the monolayer of RD cells were much bigger and well defined than those observed in the
Vero cells. However, the mean measurements of diameters of the two selected plaques (big and small)
in the Box and Whisker plot did not overlap which indicated the successful isolation of two distinct
populations. Recently, a study characterised three isolates of Zika Virus (ZIKV) which exhibited three
plaque sizes, namely: big, small and medium plaques [39]. Additionally, an African horse sickness
virus (AFHS) population was characterised and was also shown to harbour three distinct plaque size
variants [40]. As such, it is very likely that the EV-A71/WT population could be harbouring a variant
of medium plaque size. which would be expected to exhibit a mean diameter lying between the
non-overlapping diameter sizes of the EV-A71/BP and EV-A71/SP recorded in this study.
In the current investigation, it was shown that both variants displayed different growth kinetics
in the RD and Vero cells. The susceptible nature of the RD cells to EV-A71 infection [38] coupled with
the time frame of the infection (72 h) gave the EV-A71 plaque variants an advantage in infecting RD
cells and propagating to a greater extent. It caused greater cell death (CPE) in a shorter interval of
time when compared to the EV-A71 plaque variants in Vero cells. The longer adaptation to Vero cells
could have led to the disparity in the growth kinetics and viral titres observed between RD and Vero
cells. It is likely that full cytopathic effects (CPE) have occurred in the RD cells significantly before Vero
cells. Plaque sizes have previously been presented as an effective indicator of virulence [41]. More
specifically within the picornaviruses, a correlation was found to exist between virulence and plaque
sizes whereby large plaque variants were found to be more virulent than small plaque variants [42].
Hence, it is postulated that the homogeneous populations of both the EV-A71/BP and EV-A71/SP
variants would also exhibit differences in their individual replicative and infective abilities.
The most striking element of the growth kinetics study was that the EV-A71/WT displayed
higher growth kinetics when compared to the EV-A71/BP and EV-A71/SP variants. It was suspected
that the EV-A71/WT population exhibited better viral fitness which might have accounted for the
elevated rates of replication and infectivity in both RD and Vero cells. As such, increased viral fitness
of an RNA virus such as EV-A71 has been previously shown to be related to the phenomenon of
quasi-species [43]. The phenomenon of quasi-species refers to an RNA population consisting of
an ensemble of genetically related genomes often constituting a broad spectrum of mutants [44,45].
Mutants with varying levels of infectivity were generated from the wild-type population through the
high mutation rates brought about by the low replication fidelity of the RNA polymerase [46]. Recently,
Huang et al. (2017) provided the first indication of the occurrence of quasi-species of EV-A71 whereby
the parental population comprised different strains which coexisted, and they displayed high viral
growth and fitness in neuronal cells [43]. Therefore, it would be plausible that a similar scenario was
at play in this study whereby the EV-A71/WT sub-genotype B4 strain 41 harboured plaque variants
which exhibited cooperative behaviour for survival. A more in-depth analysis would be required to
verify the existence of how many quasi-species were present in the EV-A71 sub-genotype B4 strain
41 population and the extent of their cooperative behaviour in both RD and Vero cells.
The in vitro rates of RNA replication also confirmed that the EV-A71/SP variant displayed the
lowest ability to infect and replicate in RD and Vero cells at all time points of sampling. This could
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be due to the EV-A71/SP variant itself, whereby it might have exhibited a defective nature of viral
binding and cell-to-cell spread which would explain the lower replication kinetics and rate of infectivity
recorded in this study. Similar cases of defective small plaques were previously reported for other RNA
viruses such as West Nile virus (WNV) and Chikungunya (CHIKV), whereby it was postulated that the
small plaque variant existed as a minor fraction of the quasi-species population which exhibited lower
viral fitness when isolated and characterized in vitro and in vivo [33,35]. Additionally, the sudden
rise at 24 hpi of the viral copy number in Vero cells could be associated with the slow growth rate of
the EV-A71 virus in the latter. Since the original isolation of all the plaque variants in this study was
initially performed in a monolayer of RD cells followed by their subsequent infection in Vero cells, it is
suspected that a degree of in vitro adaptation occurred in the EV-A71/WT and the two plaque variants
in Vero cells before the RNA copy number peaked after 24 hpi. Similar observations were made in
another study where alternating growth and isolation of ZIKV plaque variants in mosquito cell lines
(C6/36 cells) and their subsequent infections in the mammalian cell line (Vero cells) caused the ZIKV
isolates to undergo a period of in vitro adaptation before peak replicative and infective titres were
achieved [39].
Interestingly, it is suspected that the disparity observed between RD and Vero cells reflected the
physiological differences of the host cells [39]. A previous study showed that RD cells exhibited higher
levels of the SCARB-2 cellular receptor [47]. Indeed, it is a well-known fact that cell lines of human
origins such as RD cells are rich in expressions of receptors that enable EV-A71 to enter cells [48,49].
However, contrary to RD cells which utilise SCARB2 as a major receptor for EV-A71 infection, Vero
cells have been shown to utilise other receptors [50]. Hence, the replication of EV-A71 might have
been hindered due to the cellular receptor restrictions on the viral spread, hence accounting for the
lower replication efficiency in the Vero cells. The recent elucidation of the structure of SCARB2 through
cryo-electron microscopy revealed that the main sites of contact with the virion of EV-A71 were in the
GH loop of VP1 and EF loop of VP2 [51]. This suggested that spontaneous mutations in the EV-A71/SP
isolated from RD cells had to adapt to different cell receptors on the Vero cells and this might have
been responsible for the difference observed in the growth kinetics and viral binding assays conducted.
However, to strengthen this hypothesis, further sequencing data of the EV-A71 plaque variants isolated
in Vero cells would be required in future studies. Alternative receptor requirements of the Vero cells
might have also been responsible for the discrepancy reported between the rates of replication (109 viral
copy number) and infectivity (106 PFU/mL), indicating that there might be a higher ratio of viruses
undergoing replication but they were unable to attach to effective receptors in Vero cells, hence leading
to a reduction of infectious viral particles.
The initial observation of different plaque forming abilities as reflected by different rates of
replication and the rates of infectivity of EV-A71/BP and EV-A71/SP variants indicated that there were
significant differences between them. Thus, in order to further verify the veracity of these observations,
three additional EV-A71/BP and EV-A71/SP variants were isolated from RD cells, tested in vitro and
their full genomes were sequenced. It is believed that the number of isolates in the present study
were sufficient to draw conclusions pertaining to the in vitro virulence and amino acid differences
observed in the two plaque variants. The presence of novel mutations in the VP1 which were unique
and consistent in the EV-A71/BP and EV-A71/SP variants were observed.
Previous studies by Wang et al. (2004) showed that passages of an EV-A71 4643 strain multiple
times in mice produced a mouse adapted infectious clone MP4. This strain MP4 exhibited a larger
plaque size that grew quickly and was more cytotoxic in vitro than strain 4643 [52]. However,
Huang et al. (2012) demonstrated that the introduction of a single mutation VP1-145E of glutamine to
glutamic acid or VP2-149M of lysine to methionine in the 4643 strain could lead to the production of
enlarged plaques similar to those observed on the MP4 in RD cells. In contrast, the 4643 strain bearing
the VP1-283S led to the production of small plaques which suggested that VP1-145E and VP2-149M
encouraged the spread of the MP4 virus strain. The simultaneous introduction of both mutations
(VP1-145E and VP2-149M) was reported to increase the growth kinetics and spread of the two plaque
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variants in RD cells. Moreover, the combination of two mutations was also observed to cooperatively
increase the viral infectivity which led to cytotoxicity in vitro and lethality in mice in vivo. This was
speculated to be due to a rise in viral binding ability and accumulation of EV-A71 RNA in infected
Neuro-2a cells incurred by a synergistic effect of both mutations. In our study, the EV-A71/BP and
EV-A71/SP carried different mutations in their respective genomes and thus would need reverse
genetics studies to investigate the impact of each of these mutations on the plaque morphology, as well
as the effects of these combined mutations on virulence of the EV-A71 plaque variants [53].
Other studies focusing on poliovirus revealed some striking similarities to EV-A71. For instance,
eight mutations identified in the poliovirus conferring resistance to neutralization were located in
the VP1 region. It was suggested that these regions constituted a major antigenic site involving
neutralization [54]. Hence, the presence of mutations in the VP1 of the poliovirus and the EV-A71/BP
and EV-A71/SP plaque variants indicated that they could impact the antigenicity of the EV-A71 in the
same way as the poliovirus. This deduction follows the rationale that EV-A71 has a genome structure
much like poliovirus. However, further in vitro and in vivo studies would be required to confirm this
claim. Two different Mahoney type I polioviruses were also observed to carry mutations in their VP1
(VP1-101 and VP1-102) and they had an impact on the late stage virus entry into the cell and the release
of viral RNA from the capsid. Moreover, both mutant poliovirus strains formed small plaques in HeLa
and CV1 cells. In fact, the plaque size differences between these two mutant strains and the wild type
poliovirus proved useful in demonstrating a primary defect for both mutants in cell entry. Indeed,
the first mutation, VP1-102, was suggested to affect RNA encapsidation as well as RNA release while
the other mutation, VP1-101, only affected the release of RNA from the viral capsid. Further analysis
revealed solid evidence of connections between RNA release in the host cell and RNA encapsidations
of the poliovirus. The location of the mutations in the VP1 (VP1-101 and VP1-102) suggested that
they played a direct role in the viral RNA release during cell entry and virion morphogenesis [55].
The striking similarities observed in terms of plaque sizes and lower replication rates of RNA between
the poliovirus and the EV-A71 suggested that the EV-A71 might be exhibiting similar behavioural
patterns as the poliovirus. Indeed, further investigations pertaining to the release of RNA is warranted
in the EV-A71 to confirm whether the mutations observed in the EV-A71/BP and EV-A71/SP variants
affected the release of the RNA from the capsid and its subsequent encapsidation prior to viral release
and transmission.
Homology modelling was important in this study as it showed how each of the mutations
could have affected the VP1 viral protein folding and how this might have influenced the interaction
with neighbouring amino acid residues. By analyzing the VP1 structure of both the EV-A71/BP and
EV-A71/SP variants, it can be inferred that these mutations have the ability to affect the folding capacity
of the virus. The analysis of the 3D structure also revealed that the VP1 interaction was not just
dependent on the amino acid sequence, but a tertiary structure-based interaction was necessary for
proper self-association. The most striking feature reported from the homology modelling data was
that all of the mutations present in the EV-A71/BP and the EV-A71/SP variants were located on the
capsid surface of the VP1 which was important in virus interactions with the host cells.
Like other RNA viruses, EV-A71 has been shown to exist as a quasi-species population due to
the low fidelity of the RNA-dependent RNA polymerase [23,45]. Thus, the high genetic plasticity
allowed EV-A71 to mutate in response to the changes in the environment [56]. In the present study,
four mutations were present in the EV-A71/BP variant and three mutations in the EV-A71/SP variant.
The mutation initially discovered at position 97 in the BC loop was postulated to be a hotspot
due to its recurring nature in the EV-A71/BP and EV-A71/SP variants. The BC loop is known to be
a dominant immunogenic region (residue 96–102) for enteroviruses such as poliovirus, EV-A71 and
coxsackie viruses [57,58]. Besides its immunogenic role, the BC loop region of VP1 was also identified
as a determinant of host adaptation in the poliovirus [59,60]. As such, a previous in vitro study has
successfully demonstrated that substitution at position 97 (97R) in the VP1 conferred a significant
advantage to EV-A71 to grow in neural-derived cells independent of the virus lineage [61].
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In addition, N104S observed in the EV-A71/BP variant is also of particular interest due to its
location near the 5-fold axis on the surface of the capsid. Lyu et al. (2015) reported that amino residues
of the EV-A71 genotype C4 (AH08/06; GenBank accession no. HQ611148) with residues at position 95
to 105 were located on the surface of the capsid protein near the 5-fold axis [62]. The “canyon” is a
depression that encircled the 5-fold axes on the surface of EV-A71 that harboured the receptor binding
site [63]. This is of relative importance as the virus binding to cell receptors occurred in the canyon-like
depression surrounding the 5-fold axis area [64]. Subsequently, this allowed conformational changes
in the virus, leading to externalization of the VP1 N-terminus and VP4 which allowed the extrusion
of the viral genome in the cytoplasm [65]. Thus, the N104S might exert an impact on the EV-A71/BP
variant binding to the host cells due to its proximity to the canyon.
Nishimura et al. (2013) previously presented evidence that the virus-receptor interaction was
dependent on amino acid residues VP1-145 and VP1-244. Binding of the EV-A71 to the cell receptor,
PSGL-1, was dependent on VP1-145 which was found in the DE loop of the VP1 and it functioned
by influencing the orientation of the lysine, Lys244, which was located within the HI loop on the
viral surface. It was proposed that VP1-145 mediated virus tropism by altering the availability of the
positively charged lysine side chain to bind to the negatively charged sulphated N-terminus of PSGL-1,
thereby affecting the binding capacity of EV-A71 [66].
Furthermore, the amino acid residue at position 237 was observed to interact with a neighbouring
glycine residue at position 105, Gly105. Substitution of Asn237 with Thr237 caused the Gly105 residue
to be oriented in such a way that hydrogen bonding became possible. Interestingly, Gly105 is one of
the residues that made up the hydrophobic β-barrel core of the VP1. The pocket factor binding site is
located inside the β-barrel core region of the VP1 that holds the fatty acid molecule and sits below the
canyon harbouring the receptor binding site [67,68]. Hence, it is possible that the hydrogen bonding
with Gly105 altered the hydrophobic state of the β-barrel core and ultimately affected the viral binding
capability. Indeed, analysis of the 3D structure of the EV-A71 revealed that the core structure of the
β-barrel core was significantly smaller in the EV-A71/SP variant than the EV-A71/WT.
The mutation exhibiting the most significant change in the EV-A71/BP variant was N282D whereby
the substitution resulted in the presence of a negatively charged aspartic acid at position 282 (Asp282) of
the C-terminus of the VP1 of EV-A71/BP variant. Meanwhile, the EV-A71/SP variant was also observed
to display the substitution Ala292 at the C-terminus of the VP1. Indeed, several other viruses have been
reported to accumulate mutations on the surface of major surface proteins which resulted in antigenic
drift. The sequential antigenic drift of influenza virus via the evolution of the hemagglutinin (HA)
protein is a well-illustrated example of antigenic drift [69]. While enteroviruses such as poliovirus
(PV) and EV-A71 do not often display antigenic drift in order to escape immune mechanisms, they
do exhibit evolving antigenic properties [70]. For instance, the oral polio vaccine (OPV) strain has
been shown to mutate and gave rise to pathogenic vaccine-derived poliovirus (VDPV) strains which
acquired amino acid substitutions as an evolutionary response to immunological pressure [71]. It is
likely that mutations such as N282D might exhibit altered antigenic properties due to its exposed
location on the VP1 protein. As antigenic changes in EV-A71 are believed to occur very often in
naturally occurring RNA viruses, these mutations highlighted the importance of possible alterations in
antigenic sites which are responsible for viral antigenicity. The mutations that could lead to possible
altered antigenicity would require further investigations.
The extent of the changes in the secondary structure were also observed to affect the GH loop of
the EV-A71 VP1 structure in both the EV-A71/BP and EV-A71/SP variants. Studies have reported that
the GH loop is typically a small α-helix [72]. However, a loss of the α-helix was observed as it was
altered to a 310-helix structure in the EV-A71/BP variant and a coiled structure in the EV-A71/SP variant.
This loss of α-helix is of particular importance as any changes in the VP1 that led to alterations of the
GH loop might have an impact on the viral binding ability of the virus as well as affecting its viral
uncoating process. The VP1 is the main constituent of the canyon and hydrophobic pocket. Variations
in the amino acids of the VP1 especially on the inner surface of the canyon would have a strong impact
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on the binding of the virus to the receptor and thus influence the viral load and infectivity in the
host [73]. More specifically, the role of the GH loop in the VP1 was identified as an adaptor-sensor for
cellular receptor attachment which preceded uncoating mechanisms [68].
Lyu et al. (2015) reported that the mutations in the VP1 of the EV-A71 genotype C4 led to changes
in the GH loop from 310-helix conformation to a loop structure from amino acid residues 218–221.
In other capsid proteins such as VP0, amino acid residues 218–221 also changed from helical structure to
a loop conformation following conformational changes within the protein structure [74]. These findings
are very similar to what was observed in the VP1 of the EV-A71/BP variant of this study. Hence, it
is not uncommon for mutations in the VP1 to impact the conformation of the VP1 protein and in
particular, the GH loop. It is interesting to note that the Pro213 mutation led to the alteration of the GH
loop of CV-A10 as it formed a loop structure rather than the typical α-helix conformation observed in
enteroviruses such as EV-A71 and CV-A16 [72]. In turn, this led to the shaping of a different canyon
environment in the CV-A10 virus. In the current investigation, similar findings were also observed in
the EV-A71/SP variant which formed a coiled GH loop rather than displaying an α-helix. It would be
interesting to further explore whether the coiled GH loop structure of the EV-A71/SP variant led to the
altered canyon environment as observed by Chen et al. (2019).
On the other hand, there is a possibility that the changes in the secondary structure of the VP1 by
the hydrogen bonding interactions due to the mutations might have affected the viral uncoating of the
EV-A71 after viral binding and prior to RNA replication. However, the extent to which viral uncoating
was hindered as a result of the mutations still remained to be assessed. This claim is in agreement
with a previous study which pointed out that mutations affected the capacity of the viral genome to be
released after a series of conformational re-arrangements. Indeed, the release of the RNA genome by
poliovirus was preceded by the externalization of the VP1 N-terminus and the VP4 which formed a
channel to enable the safe transfer of the viral genome [65,75,76]. Lyu et al. (2014) also suggested that
the BC, EF and HI loops played an important role in the externalization of the VP1 protein for viral
uncoating [62]. Therefore, it could be suggested that alterations in the VP1 structure of the EV-A71/BP
and EV-A71/SP variants might have affected the viral uncoating process.
Other studies have also reported that modifications in the VP1 through the replacement of amino
acids within the GH loop might have influenced how other capsid proteins such as VP2, VP3 and
VP4 might associate to form the T = 3 arrangement. For instance, Lyu et al. (2015) reported that the
replacement of residues at VP1 GH loop was able to cause the re-arrangement of local interactions
which was propagated to other capsid regions and led to conformational changes locally within the
VP1 and remotely in other capsid proteins such as VP0 and VP3 [74].
By analysis of the VP1 structure of both the EV-A71/BP and EV-A71/SP variants and the impact of
spontaneous mutations on viral folding, the data suggested that these mutations had the ability to
affect the binding capacity of the virus to the RD and Vero cell receptors due to an altered GH loop or
smaller hydrophobic pocket. The EV-A71/SP variant exhibited the least binding capability (reduction
of 17%) due to its smaller hydrophobic pocket and the altered GH loop.
Huang et al. (2015) identified substitutions of amino acids at VP1-98K, VP1-145Q and VP1-164E
which influenced the antigenic properties of EV-A71 synergistically [70]. Similar trends were also
observed in different picornaviruses whereby target mutations introduced in the VP1 led to defective
viral binding with susceptible cells [77,78]. There is a possibility that the mutations identified in the
EV-A71/SP variant could be adopting similar behaviour to affect the viral binding ability of the virus.
However, there were lesser binding of the EV-A71/BP and EV-A71/SP variants in Vero when
compared to RD cells. This would imply a lower frequency of viral entry of the EV-A71/WT, EV-A71/BP
and EV-A71/SP variants into Vero cells as well as reduced infectivity in contrast to the RD cells. Cordey
et al. (2012) suggested that such an observation implied that compensatory events might have occurred
in subsequent stages of the virus life cycle such as RNA replication or virion assembly [61]. It appears
that the mutations located in the VP1 of the EV-A71/SP variant affected its binding capability. However,
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it cannot be ruled out that these substitutions might also affect other stages prior to RNA replication
such as viral uncoating or later stages such as virion assembly [61].
Future Directions
To further complement this study, it would be interesting to observe the plaque morphology of
the EV-A71/WT and the plaque variants in additional cell lines such as human neuroblastoma cells,
SK-N-SH and SH-SY5Y, in which EV-A71 was shown to aggressively replicate and display efficient
production of viruses [38,79]. The exceedingly large population size of EV-A71 (108 to 109) in RD
cells would affect its evolutionary outcome [80]. Therefore, to fully understand and explain the
behaviour and growth properties of the EV-A71 virus in a population, knowledge of a larger amount
of genetic information is required [81]. Hence, there is a need to further strengthen the observation
of the role of these consistent mutations on the in vitro behaviour of the EV-A71/BP and EV-A71/SP
variants. The course of action would be to sequence more EV-A71/BP and EV-A71/SP variants that were
passaged at length in both RD and Vero cells and sequence them so as to assess whether there are any
more mutations that might have arisen as a result of selective environmental pressure or cell-specific
mutations in the plaque variants. This would effectively narrow the search to find specific mutation(s)
being the molecular determinant of plaque size or virulence of the small plaque variant. Another
approach to explore would be through next generation sequencing (NGS) which provides an in-depth
analysis of the frequency of occurrence and the nucleotide sequence similarity of the variants within a
population. An NGS approach would give an idea of the overall genetic coverage of the mutations by
analysing the entire population of the EV-A71/WT sub-genotype B4 strain 41. Since the presence of two
quasi-species in the WT population (EV-A71/BP and EV-A71/SP) were displaying different mutations
and the genotypes were stable upon passages, identifying the frequency of occurrence of additional
variants and identifying the amino acid substitutions in the other variants present in the population
would help steer the study in the right direction.
5. Conclusions
In conclusion, this study shows the successful isolation of at least two EV-A71 plaque variants of
different sizes from the EV-A71/WT population of sub-genotype B4 strain 41. Successful characterization
of the plaque variants in two cell lines showed that the EV-A71/BP and EV-A71/SP variants have
different levels of virulence in RD and Vero cells. Furthermore, the results supported the hypothesis
that there were novel spontaneous mutations in the VP1 which were unique and consistent in the
EV-A71/BP and EV-A71/SP variants. These mutations were responsible for differences in the levels of
in vitro virulence observed in this study. Homology modelling analysis indicated that the spontaneous
mutations observed in the EV-A71 plaque variants affected the folding capacity of the VP1 capsid
protein. The mutations present in the EV-A71/SP variant have led to the alteration of its GH loop and
gave rise to a smaller hydrophobic pocket which could potentially affect the viral binding ability to
host cell receptors. Indeed, the viral binding assays revealed that the EV-A71/SP variant showed the
lowest binding capability in both RD and Vero cells when compared to the EV-A71/BP variant and the
EV-A71/WT.
Despite altered structural differences observed in both the EV-A71/BP and EV-A71/SP variants, the
EV-A71/BP did not show drastic changes in the in vitro virulence and binding capability as compared to
the EV-A71/SP variant. Indeed, this study indicated that the three mutations present in the EV-A71/SP
had a more significant impact on the in vitro virulence and binding ability to the cell receptors when
compared to both the EV-A71/WT and the EV-A71/BP variant. As such, the mutations of the EV-A71/SP
variant should be significant and investigated individually via site-directed mutagenesis (SDM) to
further clarify whether they possess significant attenuation of virulence or could alter antigenicity.
Further studies should be carried out to quantify the viral attenuation effect of each of the three
spontaneous mutations uncovered in this variant via SDM. In view of the rising concerns over EV-A71
infections which had caused fatal large-scale outbreaks in the Asia Pacific region, the results obtained
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in this current investigation could pave the way towards the rational design of a genetically stable LAV
vaccine against EV-A71 infections.
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